Payment overview · 2025
General Payments
$1,364.63
48 reported records · 13 companies
Healthcare provider profile · identity verified
Charles Saha, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · NEW YORK, NY · NPI 1174566699
Verified facts
What the public records show
CMS Open Payments records show Charles Saha, M.D received $1,364.63 in general payments during 2025 across 48 reported records.
QOL Medical, LLC accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $444.53 | 32.6% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $359.45 | 26.3% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.49 | 8.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $107.53 | 7.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $79.83 | 5.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.15 | 5.4% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $48.21 | 3.5% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.39 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.32 | 2.1% | 2 | 2025 |
| Vibrant Gastro, Inc. | Unresolved — no canonical attribution shown | $23.80 | 1.7% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $23.23 | 1.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.18 | 1.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.52 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,364.63 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $444.53 | 13 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $160.85 | 3 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $114.15 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $107.53 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $100.01 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $50.39 | 2 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $48.21 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.33 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.33 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.33 | 1 | 2025 |
Source payment records
|
|||||
| AMS 800 Artificial Urinary Sphincter Normalized: ams 800 artificial urinary sphincter |
Device | Boston Scientific Corporation | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.32 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| Vibrant Starter Kit Normalized: vibrant starter kit |
Device | Vibrant Gastro, Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 268 | 68 |
| Omeprazole | Omeprazole | 168 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 85 | 20 |
| Famotidine | Famotidine | 80 | 22 |
| Metformin Hcl Er | Metformin Hcl | 80 | 29 |
| Metformin Hcl | Metformin Hcl | 77 | 18 |
| Synthroid | Levothyroxine Sodium | 74 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 16 |
| Simvastatin | Simvastatin | 55 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 22 |
| Lisinopril | Lisinopril | 46 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | suppressed |
| Valsartan | Valsartan | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 39 | suppressed |
| Azithromycin | Azithromycin | 37 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 18 |
| Azelastine Hcl | Azelastine Hcl | 27 | 15 |
| Losartan Potassium | Losartan Potassium | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Clenpiq | Sod Picosulf/Mag Ox/Citric Ac | 23 | 22 |
| Gabapentin | Gabapentin | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Edluar | Zolpidem Tartrate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,364.63 · 48 records | QOL Medical, LLC | ABRYSVO, AMS 800 Artificial Urinary Sphincter, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, ENTYVIO, KISUNLA, LINZESS, NEXLETOL, NURTEC ODT, PREVNAR 20, QULIPTA, REZDIFFRA, RINVOQ, SKYRIZI, Sucraid, TRELEGY ELLIPTA, VELSIPITY, VIBERZI, Vibrant Starter Kit, XELJANZ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error